Selective silencing of HRAS by HRAS-LV also led to selective inhibition of bladder cancer cell proliferation, migration, and invasion, while increasing apoptotic cancer cell death compared to NC-LV-treated groups, showing that a TERT promoter-driven and CRISPR/Cas9-based genetic circuit can be a promising strategy to selectively silence oncogenes of cancer. This evidence concerns the gene TERT and urinary bladder carcinoma.